Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Fish and Richardson
Moodys
Boehringer Ingelheim
Julphar
Federal Trade Commission
Johnson and Johnson
Medtronic
Covington

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: RE44872

« Back to Dashboard

Summary for Patent: RE44872
Title:Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Abstract: (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide or its salt shows a potent bladder relaxation effect in "isolated rat bladder smooth muscle relaxation test", dose-dependently lowers the contraction frequency of rhythmic bladder contractions in "rat rhythmic bladder contraction measurement test" and, moreover, prolongs the urination intervals in "urination functions measurement test on cyclophosphamide-induced overactive bladder model rat". Owing to these effects, the above compound is useful as a remedy for ovaractive bladder.
Inventor(s): Takasu; Toshiyuki (Tsukubamirai, JP), Sato; Shuichi (Tsukuba, JP), Ukai; Masashi (Tsukuba, JP), Maruyama; Tatsuya (Tsuchiura, JP), Shibasaki; Masayuki (Tokyo, JP)
Assignee: Astellas Pharma Inc. (Tokyo, JP)
Application Number:13/542,308
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent RE44872
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent RE44872

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Apgdi MYRBETRIQ mirabegron TABLET, EXTENDED RELEASE;ORAL 202611-001 Jun 28, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY ➤ Try a Free Trial
Apgdi MYRBETRIQ mirabegron TABLET, EXTENDED RELEASE;ORAL 202611-002 Jun 28, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: RE44872

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2002-323792Nov 7, 2002
PCT Information
PCT FiledNovember 04, 2003PCT Application Number:PCT/JP03/14065
PCT Publication Date:May 21, 2004PCT Publication Number: WO2004/041276

Non-Orange Book US Patents Family Members for Patent RE44872

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,750,029 Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient ➤ Try a Free Trial
8,835,474 Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent RE44872

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 1559427 ➤ Try a Free Trial
Russian Federation 2321401 ➤ Try a Free Trial
Russian Federation 2005117367 ➤ Try a Free Trial
Portugal 1559427 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
US Army
Queensland Health
AstraZeneca
Fish and Richardson
Farmers Insurance
McKinsey
UBS
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.